Esperion Therapeutics, Inc.
ESPRDelisted Jul 13, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001434868
Esperion Therapeutics, Inc. was delisted on Jul 13, 2026; its insiders filed their last Form 4 on Jul 13, 2026; 191 institutions reported holding it in 13F filings for Q2 2026, worth $646.8M in total; Soros Fund Management was the only superinvestor holding it.
Q2 2021 vs. Q1 2021
How the institutions holding Esperion Therapeutics, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 156 | 142 | −14 |
| Shares | 28.7M | 28.3M | −370.4K (−1.3%) |
| Value | $805.3M | $599.4M | −$205.9M (−25.6%) |
New holders (18)
Institutions that held Esperion Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Avidity Partners Management LP | 400,000 | $8.46M | 0.23% |
| Wolverine Asset Management LLC | 75,000 | $1.59M | 0.01% |
| Voloridge Investment Management, LLC | 64,794 | $1.37M | 0.01% |
| Schonfeld Strategic Advisors LLC | 60,065 | $1.27M | 0.01% |
| Maverick Capital LtdSuperinvestorMaverick Capital | 44,992 | $952.0K | 0.01% |
| M&G Investment Management Ltd | 36,056 | $757.0K | 0.00% |
| Lazard Asset Management LLC | 27,000 | $571.0K | 0.00% |
| Virtu Financial LLC | 13,480 | $285.0K | 0.03% |
| Invesco Ltd. | 10,630 | $225.0K | 0.00% |
| Occudo Quantitative Strategies LP | 10,583 | $224.0K | 0.03% |
| Point72 Hong Kong Ltd | 7,577 | $160.0K | 0.01% |
| SG3 Management, LLC | 4,000 | $85.0K | 0.04% |
| Dark Forest Capital Management LP | 984 | $21.0K | 0.01% |
| Creative Financial Designs Inc | 275 | $6.00K | 0.00% |
| Parisi Gray Wealth Management | 180 | $4.00K | 0.00% |
| TCI Wealth Advisors, Inc. | 95 | $2.00K | 0.00% |
| McCarthy Asset Management, Inc. | 100 | $2.00K | 0.00% |
| Quadrant Capital Group LLC | 21 | $0 | 0.00% |
Sold out (32)
Institutions that held Esperion Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.